Biotech Values

[microcapfun]

>>AMLN – A tidbit from NVO’s UBS webcast that may interest you: the presenter said that inhaled insulin is all but doomed to be a non-factor in the market due to the advent of GLP-1 drugs. The premise is that GLP-1 drugs will routinely be added to a regimen that includes long-acting, basal insulin.<<

Has anyone seen a recent article comparing the long-lasting GLP-1 drugs? A table comparing halflife and phase of study would be nice.

I know GSK has one in a 300 patient P2b study that Human Genome Sciences has some rights to. (Used to be called Albugon.) But Novo Nordisk is way ahead of GSK:
>>Novo Nordisk today announced clinical results from the second and third of five phase 3 studies with liraglutide - the once-daily human GLP-1 analogue. The two 26-week studies are part of the LEAD® (Liraglutide Effect and Action in Diabetes) programme and comprised 2,132 patients in total.<<
http://www.glucagon.com/liraglutide_phase_3_lead_data.htm

micro